Citius Oncology Overview
Latest P/E ratio for Citius Oncology: -1.76 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-1.76
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, CTOR shows a P/E ratio of -1.76. That is below the sector sector average of 30.66. Scroll down for historical charts and peer comparison views.
The its sector sector average P/E ratio is about 30.66. Citius Oncology is at -1.76, which is lower that average. That is roughly 105.7% below the sector mean. Use the comparison chart on this page to see how CTOR stacks up against individual peers as well.
Investors watch CTOR's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Citius Oncology's latest reading is -1.76. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Citius Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -1.76) with ownership activity and broader fundamentals.
